Figure 1 Kaplan Meier survival function by baseline ART regimen
Figure 1 Kaplan Meier survival function by baseline ART regimen
Variables |
|
Non Zidovudine |
Zidovudine |
|
|
|
(N=308) |
(N=308) |
|
|
|
[n (%)] |
[n (%)] |
|
|
|
|
|
|
Sex |
Male |
107 (34.74) |
108 (34.09) |
|
|
Female |
201 (65.26) |
200 (64.94) |
|
Educational |
No education |
80 (25.97) |
78 |
(25.32) |
status |
Primary education |
159 (51.62) |
193 (62.66) |
|
|
||||
|
Secondary education |
39 (12.66) |
19 |
(6.17) |
|
Tertiary education |
30 (9.74) |
18 |
(5.84) |
Employment |
Non employed |
120 (38.96) |
97 |
(31.49) |
|
Employed |
188 (61.04) |
211(68.51) |
|
| Place of residence | Rural |
112(36.36) |
102(33.22) |
|
Urban |
196(63.64) |
205(66.78) |
||
|
||||
Anemia |
Censored |
234 (75.97) |
181(58.77) |
|
|
Anemia |
74(24.03) |
127(41.23) |
|
Opportunistic |
No |
151(49.03) |
91(29.55) |
|
infection |
Yes |
157(50.97) |
217(70.45) |
|
|
||||
Tuberculosis |
No |
237(76.95) |
213(69.16) |
|
infection |
Yes |
71(23.05) |
95(30.84) |
|
|
||||
Age |
Age range |
16 – 68 years |
17 |
– 71 years |
Baseline CD4 count |
Count range |
85 – 340 cells/mm3 |
50 |
– 295 cells/mm3 |
|
|
|
|
|
|
|
|
|
|
Table1 Baseline Socio-demographic and clinical characteristics of patients who were taking ART in St. Paul's and ALERT hospital during January 2008 – December 2012 (n=616)
Variables |
|
Non Zidovudine |
Zidovudine |
|
|
|
(N=308) |
(N=308) |
|
|
|
[n (%)] |
[n (%)] |
|
|
|
|
|
|
Oral or vaginal Candidiasis |
No |
258(83.77) |
223(72.40) |
|
Yes |
50(16.23) |
85(27.60) |
||
|
||||
Chronic Diarrhea |
No |
274(88.96) |
249(80.84) |
|
Yes |
34(11.04) |
59(19.16) |
||
|
||||
Tuberculosis treatment |
No |
246(79.87) |
213(69.16) |
|
Yes |
62(20.13) |
95(30.84) |
||
|
||||
Baseline Weight |
Greater than or equal to 60 |
60(19.48) |
57(18.51) |
|
Kg |
|
|
||
|
Less than 60 Kg |
248(80.52) |
251 (81.49) |
|
Baseline functional status |
Working |
53(17.21) |
54 (17.53) |
|
Ambulatory |
233(75.65) |
237 (76.95) |
||
|
|
|
||
|
Bed ridden |
22(7.14) |
17 (5.52) |
|
CD4 count |
Greater than or equal to 200 |
51(67.86) |
106 (68.51) |
|
|
cells |
|
|
|
|
Less than 200 cells |
257(32.14) |
202 (31.49) |
|
Baseline ALT |
Normal |
281(91.23) |
238 (77.27) |
|
|
Abnormal |
27(8.77) |
70 (22.73) |
|
Baseline AST |
Normal |
208(67.53) |
197 (63.96) |
|
|
Abnormal |
100(32.47) |
111 (36.04) |
|
Table2 Baseline clinical and laboratory characteristics of patients who were taking ART in St. Paul's and ALERT hospital during January 2008 – December 2012 (n=616)
Variables |
|
UHR [95% CI] |
P-value |
AHR [95% CI] |
P-value |
|
|
|
|
|
|
|
|
Sex |
Male |
1.00 |
|
|
|
|
|
Female |
1.44 [1.0663- 1.9482] |
0.002 |
-- |
|
|
Age |
|
1.014 [1.0006 - 1.0267] |
0.004 |
1.017 [1.0041 - 1.0307] |
0.011 |
|
Oral or |
No |
1.00 |
|
|
|
|
vaginal Candidiasis |
Yes |
1.74 [1.2969 - 2.3235] |
0.001 |
-- |
-- |
|
|
|
|
|
|
||
Chronic |
No |
1.00 |
|
1.00 |
|
|
Diarrhea |
Yes |
2.08 [1.5167 - 2.8659] |
0.001 |
1.85 [1.3439 - 2.5695] |
0.001 |
|
|
||||||
Baseline ART |
Non ZDV regimen |
1.00 |
|
1.00 |
|
|
ZDV regimen |
1.71 [1.2838 - 2.2776] |
0.001 |
2.84 [1.5224 - 5.3137] |
0.001 |
||
regimen |
||||||
|
|
|
|
|
||
Baseline functional status
|
Working |
1.00 |
-- |
1.00 |
-- |
|
Ambulatory |
0.71 [0.5038 - 0.9973] |
0.048 |
0.67 [0.4783 - 0.9597] |
0.028 |
||
Bed ridden |
0.57 [0.2931 - 1.1068] |
0.097 |
0.47 [0.2407 - 0.9228] |
0.028 |
||
Baseline WHO staging |
Stage I |
1.00 |
-- |
|
|
|
Stage II |
0.98 [0.6443 - 1.4762] |
0.906 |
|
|
||
|
|
|||||
|
|
|
|
|
||
|
Stage III |
1.95 [1.1926 - 3.2068] |
0.008 |
-- |
-- |
|
|
Stage IV |
1.65 [0.9608 - 2.8337] |
0.007 |
|
|
|
Baseline |
>= 200 cell |
1.00 |
|
1.00 |
|
|
CD4 count |
|
|
0.001 |
|
0.001 |
|
|
|
|
|
|||
|
< 200 cells |
5.91 [4.3346 - 8.0501] |
|
4.96 [3.4144 - 7.2049] |
|
|
|
|
|
|
|
|
Table3 Shows the unadjusted and adjusted hazard ratios of socio demographic, clinical and laboratory variables